Aspirin resistance: biological and clinical implications (Q37089560)

18 August 2017

1 reference

title

Aspirin resistance: biological and clinical implications (English)

1 reference

18 August 2017

1 reference

Stephanie Tseeng

1

1 reference

18 August 2017

Rohit Arora

series ordinal

2

1 reference

18 August 2017

publication date

1 March 2008

1 reference

Journal of Cardiovascular Pharmacology and Therapeutics

18 August 2017

published in

1 reference

18 August 2017

volume

13

1 reference

18 August 2017

issue

1

1 reference

18 August 2017

page(s)

5-12

1 reference

Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177/1074248407310869

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248407310869

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248407310869

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248407310869

Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248407310869

Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248407310869

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248407310869

Narrative review: aspirin resistance and its clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248407310869

The effect of chronic platelet inhibition with low-dose aspirin on atherosclerotic progression and acute thrombosis: clinical evidence from the Physicians' Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248407310869

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248407310869

Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248407310869

Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248407310869

Profile and prevalence of aspirin resistance in patients with cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248407310869

Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248407310869

Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248407310869

The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248407310869

High frequency of aspirin resistance in patients with acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248407310869

The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248407310869

Antiplatelet effect of aspirin in patients with cerebrovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248407310869

Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248407310869

Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248407310869

Effect of aspirin treatment in patients with peripheral arterial disease monitored with the platelet function analyzer PFA-100

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248407310869

Laboratory detection of 'aspirin resistance': what test should we use (if any)?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248407310869

Monitoring acetylsalicylic acid effects with the platelet function analyzer PFA-100

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248407310869

Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248407310869

A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248407310869

Aspirin resistance: definition, mechanisms and clinical read-outs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248407310869

Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248407310869

Paired analysis of urinary thromboxane B2 metabolites in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248407310869

Platelet-active drugs : the relationships among dose, effectiveness, and side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248407310869

Effects of mental and physical stress on platelet function in patients with stable angina pectoris and healthy controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248407310869

Norepinephrine-induced human platelet activation in vivo is only partly counteracted by aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248407310869

Role of catecholamines in platelet function: pathophysiological and clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248407310869

The role of exercise on platelet aggregation in patients with stable coronary artery disease: exercise induces aspirin resistant platelet activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248407310869

Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248407310869

Aspirin resistance and a single gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248407310869

Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/1074248407310869

21 January 2018

Identifiers

DOI

10.1177/1074248407310869

1 reference

18 August 2017

1 reference